Harvard Center of Polycystic Kidney Disease Research

多囊肾病（PKD）是一种常见的遗传性疾病，其特征是肾脏中充满液体的囊肿的发展，具有高发病率和死亡率。常染色体显性PKD （ADPKD）影响约1:10 000个体，而常染色体隐性PKD （ARPKD）约为1:20 000活产婴儿。囊肿形成的分子机制尚不清楚。主任实验室最近的工作表明，多囊蛋白-1和-2作为受体通道复合物，介导G蛋白和钙信号和机械感觉。该主任开发了许多具有人类ADPKD基因同源突变的小鼠模型，并从这些小鼠突变体及其野生型幼崽中产生细胞系。利用这些试剂和主任实验室开发的其他试剂，中心研究人员将探索人类多囊肾病的分子机制。项目1 （Denker博士）将使用生化、细胞生物学和遗传学方法来了解异源三聚体G蛋白在PKD中的作用。在项目2中，Kreidberg博士将使用细胞和分子生物学方法的结合来了解钙粘蛋白和整合素在多囊肾病发病机制中的作用。在项目3中，周博士将使用生化和细胞生物学方法来了解纤维囊蛋白/多导蛋白（FPC）在PKD中的作用，并与多囊蛋白在PKD中的作用进行比较。这些项目中的每一个都将得到一个核心设施的支持，该设施将提供最新的分子成像支持和一个行政核心。

Polycystic kidney disease (PKD) is a common genetic disease that is characterized by the development of fluid filled cysts in the kidney and is associated with high morbidity and mortality. Autosomal dominant PKD (ADPKD) affects approximately 1:1000 individuals, whereas autosomal recessive PKD (ARPKD) is seen in approximately 1:20,000 live births. The molecular mechanisms underlying cyst formation remain unclear. The recent work from the Director's laboratory has shown that polycystin-1 and -2 function as a receptor channel complex that mediates G protein and calcium signaling and mechanosensation. The director has developed a number of mouse models with mutations in the mouse ortholog of the human ADPKD gene and generated cell lines from these mouse mutants and their wild type littermates. Taking advantage of these and other reagents developed in the Director's laboratory, the Center investigators will explore the molecular mechanisms underling human polycystic kidney disease. Project 1 (Dr. Denker) will use biochemical, cell biological and genetic approaches to understand the role of heterotrimeric G proteins in PKD. In Project 2 Dr. Kreidberg will use a combination of cell and molecular bioiogical approaches to understand the role of cadherins and integrins in the pathogenesis of polycystic kidney disease. In Project 3 Dr. Zhou will use biochemical and cell biological approaches to understand the role of fibrocystin/polyductin (FPC) in comparison with the roles of polycystins in PKD. Each of these projects will be supported by a Core facility that will provide most up to date support on molecular imaging and an administrative Core. The proposed studies are highly relevant to both the recessive and dominant forms of human polycystic kidney disease. Results from these studies will advance our understanding of the molecular mechanisms underlying cystogenesis and lead to the identification of novel therapeutic strategies.